Two of the five stop the cancer before it exists. Cervical and colon screening find and remove precancerous tissue, so no tumor forms; cervical screening has cut cervical cancer 60–70% 1.
The other three catch cancer early, not never. Breast, lung, and skin screening find a tumor while it's still small enough to cure. CT in heavy smokers cut lung cancer deaths 20% 2; mammography cuts breast cancer deaths 15–30% 3. Skin is the holdout: no trial has shown routine exams save lives 4.
For an average-risk adult, the full schedule fits on one card.
A pack-year is a pack a day for a year, so twenty is a pack a day for twenty years. Family history rewrites all of it: a first-degree relative with colon cancer at 45 moves your start to 35, and a BRCA mutation adds an MRI in your late twenties.
These five carry more big-trial evidence than almost any other preventive move. The first randomized colonoscopy trial cut colon cancer risk 31% in those invited to screen 9, and US cervical mortality has dropped from about 14 per 100,000 in the 1950s to 2.2 today on the back of Pap and HPV screening 10.
The whole schedule costs a couple of hours a year, and for insured Americans it's free. The Affordable Care Act mandates zero cost-sharing on task-force Grade A and B screens at the recommended interval. A Pap or stool test takes minutes; the colonoscopy is the one real chore, at 90 minutes plus a day of clear-liquid prep.
Day to day you feel nothing; the payoff is a timeline you never see. The polyp cut out at 50 was the colon cancer you didn't get at 62. The visible moment is one call: two polyps found and removed, see you in five years. Across a lifetime, staying on schedule lowers your absolute cancer-death risk by roughly half a point to a point 11.
The fine print — when to skip it, and what people get wrong
Earlier isn't always better. Some screen-found tumors would never have hurt you; 19–30% of mammography-detected breast cancers are overdiagnosed 12. Screening still saves far more than it overtreats.
More often isn't better. Annual mammograms roughly double false positives over a decade versus every two years, with no clear survival gain for average risk.
At-home stool tests aren't second-best. Done every year, their mortality benefit matches colonoscopy in modeling 13. The hard part is doing it yearly for thirty years.
One round barely helps; the benefit comes from decades of on-schedule screens. US uptake: about 70% for breast, 75% cervical, 70% colon, and just 6% for lung 14.
A clean screen means the test found nothing this time. Interval cancers grow between screens, so a new lump, blood in stool or cough, or a changing mole gets worked up regardless of when you last screened.
The organizations disagree at the edges. Radiology says annual mammograms from 40; the task force says every two years from 40 15. Real disagreement, but only at the margins.
- 1Ronco G et al. (2014). Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. The Lancet. link
- 2National Lung Screening Trial Research Team (2011). Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. New England Journal of Medicine. link
- 3Tabár L et al. (2011). Swedish Two-County Trial: Impact of Mammographic Screening on Breast Cancer Mortality during 3 Decades. Radiology. link
- 4USPSTF (2023). Screening for Skin Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. link
- 5USPSTF (2021). Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. link
- 6USPSTF (2018). Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. link
- 7USPSTF (2024). Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. link
- 8USPSTF (2021). Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. link
- 9Bretthauer M et al. (2022). Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death (NordICC). New England Journal of Medicine. link
- 10Siegel RL et al. (2024). Cancer statistics, 2024. CA: A Cancer Journal for Clinicians. link
- 11Lin JS et al. (2021). Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. link
- 12Welch HG et al. (2016). Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. New England Journal of Medicine. link
- 13Lew JB et al. (2019). Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia. The Lancet Public Health. link
- 14Wolf AMD et al. (2024). Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA: A Cancer Journal for Clinicians. link
- 15Monticciolo DL et al. (2023). Breast Cancer Screening Recommendations Inclusive of All Women at Average Risk: Update from the ACR and Society of Breast Imaging. Journal of the American College of Radiology. link
დაკავშირებული სახელმძღვანელოში (12)
- — This blood test doesn't replace the proven screens — the standard cancer schedule is the established, evidence-backed baseline it sits on top of.
- — Beyond the five cancers, the aortic-aneurysm ultrasound is another high-value age-based screen for older men.
- — Vaccines and cancer screens are the two pillars of grown-up prevention — and HPV shots prevent cancer outright.
- — Alcohol is a Group 1 carcinogen with no safe dose — which is exactly why staying on the screening schedule matters if you drink.
- — The cancer screens drop neatly into a once-a-year cadence of preventive visits.
- — Mammograms are one line on the broader adult cancer-screening schedule — don't run them in isolation.
- — Cervical screening is one line on the adult cancer-screening schedule — slot it in with the rest.
- — Colorectal screening is one line on the adult schedule — start at 45 and run to 75.
- — The shot prevents the HPV cancers; the screening schedule is how you catch the ones it can't fully cover — they work as a pair.
- — Lung screening is gated by smoking history rather than age alone — it slots into the wider screening schedule.
- — Prostate screening is the one cancer test that's a conversation, not an automatic — it sits apart from the rest.
- — Skin is the one cancer you screen yourself, monthly — the others run on a fixed clinic schedule.
Adult Cancer Screening Schedule
ACA mandates zero cost-sharing for all USPSTF Grade A/B screenings at recommended intervals for insured Americans (covers ~92% of adults). Out-of-pocket cost is occasional cost-sharing on follow-up diagnostic workup after a positive screen, plus indirect costs (travel, time off work). Trivial under $50/year for most.
Multiple large RCTs anchor each site: NLST and NELSON for lung (NLST 2011, de Koning 2020); Minnesota gFOBT, PLCO/UK FlexSig, and NordICC for colorectal (Mandel 1993, Schoen 2012, Bretthauer 2022); eight RCTs plus Tabár 30-year follow-up for breast (Tabár 2011, Marmot 2013); four European RCTs for HPV-based cervical screening (Ronco 2014). USPSTF Grade A/B endorsement is by definition Cochrane-tier. Skin screening is the exception with an I-statement (USPSTFSkin2023) — flagged in the article — but does not pull the aggregate evidence rating down.
Among the highest-confidence preventive interventions in adult medicine. USPSTF Grade A/B screenings in scope reduce cancer-specific mortality by 20–70% per site (e.g., cervical incidence down 60–70% with HPV-based screening, Ronco 2014; lung mortality down 20% with LDCT, NLST 2011; colorectal mortality reduced substantially with colonoscopy or annual FIT, Bretthauer 2022, Nishihara 2013, Mandel 1993). Absolute lifetime cancer-death reduction across all five sites for an asymptomatic adult on schedule is roughly 0.5–1% — large in life-years saved per hour of effort.
Aggregate time per year is minor — mammogram ~30 min annually or biennially, Pap ~10 min every 3–5 years, FIT ~5 min annually (or colonoscopy ~90 min plus a day of prep every 10 years), LDCT ~10 min annually for eligible smokers, plus tracking the schedule. Colonoscopy prep is the highest-friction single item. Real but minor.
Direct short-term wellness effect is small — a clean screening produces brief reassurance and resolves background uncertainty about specific cancer risks. Symmetric anxiety risk during waiting/follow-up partially offsets. Real but minor.
Modest sense of agency and peace of mind from being current on screenings; mirrored by short-term anxiety during waiting and follow-up phases. Net small positive on inner wellbeing, no felt-meaning effect.